In a statement, the FDA said that peptides marketed as sold for research use pose significant risks to patients because they have not been reviewed by the FDA before they are marketed to ensure safety, effectiveness or quality, and they are obtained without a prescription or prescriber oversight. Scott Brunner, the CEO of the Alliance for Pharmacy Compounding, says that reconstituting such drugs at home is a risky idea
It may take more time than expected, and it may require speaking with a fertility specialist to see how you can improve your sperm quality
Split your payment into manageable installments with Klarna
While newer and stronger drugs exist, Saxenda is still a safe, effective, and reliable option when used under proper medical supervision
Eli Lilly has stated it "remains confident in the differentiated benefits of tirzepatide." Facing generic competition, Novo Nordisk has taken several steps: Launch of rebranded versions In December 2025, Health Canada approved two Novo Nordisk rebranded versions on December 22: These are identical to the branded versions but come in different packaging
October 21, 2024: Judge Makes Critical Decision in Pre-Discovery Phase of Ozempic Lawsuit The judge in the federal Ozempic lawsuit (MDL 3094) denied the plaintiffs motion to require the defendants to turn over specific marketing materials early in the case
